Europe’s best-performing blue-chip inventory in 2025 is broadly anticipated to be purchased by a bigger peer, in a deal analysts say may very well be price as a lot as $23 billion.
Abivax, the French clinical-stage biotech firm growing a therapy for ulcerative colitis and Crohn’s illness, noticed shares rocket 1,681% final yr, far outpacing the Stoxx 600 index’s second-best performing inventory, mining firm Fresnillo, which rose 453%.
Now, the large query for analysts appears to be when, not if, Abivax publicizes a deal.
The inventory, listed in 2015, largely ranged between 10 and 20 euros however it wasn’t till 10 years later that it actually took off. Shares surged 510% in a day after Abivax reported the outcomes of a late-stage trial for an ulcerative colitis medication in July, beating even probably the most optimistic expectations. After these sorts of outcomes, it may very well be a strategic acquisition for any giant pharmaceutical firm with an immunology and irritation franchise.
Abivax’s lead – and solely – asset, obefazimod, was first developed as a therapy for HIV, however researchers found that its anti-inflammatory impact may have an effect on different circumstances like inflammatory bowel illness (IBD) and commenced medical trials.
Shares had been boosted much more in December as rumors emerged that the world’s most beneficial pharma firm, Eli Lilly, had its eyes set on buying Abivax. Each corporations have repeatedly declined to touch upon enterprise improvement actions.
An imminent deal?
Analysts say {that a} deal may occur any time now.
Van Lanschot Kempen analyst Sebastiaan van der Schoot advised CNBC that biotechs usually “have a comparatively small variety of workers and have no expertise with promoting a drug,” which he referred to as “a totally completely different ball recreation” to growing them.
“That is why pharma takes them out to truly leverage their infrastructure,” he stated.
The analyst added that he anticipated Abivax to commerce between the place it’s now and the place it was when rumors of a takeover first surfaced, till the annual JP Morgan Healthcare Convention on Monday, the place corporations usually announce giant offers.
Abivax shares surged in 2025, far outpacing European friends.
It comes as Massive Pharma has ramped up dealmaking in current months, because the sector faces a looming patent cliff the place among the world’s best-selling medicine lose exclusivity within the coming years.
One other issue making a deal likelier is Abivax CEO Marc de Garidel’s fame as a pacesetter who could make offers occur. He beforehand led multi-billion greenback buyouts of biotech corporations to pharma gamers like AstraZeneca and Novo Nordisk.
Requested a couple of potential acquisition, de Garidel advised CNBC’s “Europe Early Version” in December that the corporate was at all times in “dialog with Massive Pharma” however that its function was to develop the absolute best drug.
Abivax is planning to file for regulatory approval within the U.S. by the top of 2026, eyeing a possible launch by the third quarter of 2027, de Garidel stated.
The corporate is well-positioned to barter a good take care of a Massive Pharma companion, Stifel analyst Damien Choplain stated.
“Given the power of the Section III outcomes and the shortage of comparable belongings, we imagine a transaction may very well be executed forward of the upkeep information readout anticipated in Q2 2026,” he stated, referring to a second medical trial of Obefazimod which exams its efficacy over 44 weeks versus solely eight weeks.
Choplain added that almost all transactions within the IBD house have traditionally occurred for drug candidates in earlier levels of improvement. “Abivax ticks all of the containers for a strategic acquisition,” he stated.
Primarily based on comparable transactions and a peak gross sales estimate of three billion euros, Abivax’s valuation may vary between 12 billion euros and 20 billion euros ($14 billion to $23 billion), Choplain advised CNBC.
Latest offers within the IBD house embody Merck’s acquisition of Prometheus for $10.8 billion; Roche’s acquisition of Telavant for $7.1 billion; and Eli Lilly shopping for Morphic for $3.2 billion. These offers had been all for belongings in an earlier stage of improvement than Abivax’s obefazimod.
A possible best-in-class therapy
Jefferies analyst Roger Track, who would not cowl Abivax per se however tracks the IBD house intently from Boston, stated that traders’ optimism comes each from a multi-billion greenback potential marketplace for IBD therapies, in addition to from the drug candidate’s novel means of addressing it by a number of pathways.
It’s even thought-about to be a possible best-in-class therapy for ulcerative colitis, he advised CNBC in December.
The July outcomes from the trial of Obefazimod shocked traders as a result of many had not been conscious of the novel mechanism it makes use of, micro-RNA, Track stated.
A late-stage upkeep trial is anticipated within the second quarter of 2026.
Van der Schoot added that, if Abivax is assured sufficient in these upkeep outcomes, it will probably wait to be acquired after the trial is printed, “as a result of then they will ask the next worth.”
